Francesca Romana Mauro

List of Publications by Year
in descending order

176	5,395	109321	95266
papers	citations	35 h-index	68 g-index

176	176	176	5615
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent Bâ€cell lymphomas. Hematological Oncology, 2023, 41, 571-573.	1.7	0
2	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica, 2022, 107, 868-876.	3.5	31
3	Treatment with ibrutinib does not induce a <I>TP53</I> clonal evolution in chronic lymphocytic leukemia. Haematologica, 2022, 107, 334-337.	3.5	4
4	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified threeâ€factor model. American Journal of Hematology, 2022, 97, .	4.1	5
5	Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. Haematologica, 2022, 107, 1470-1473.	3.5	12
6	Use of BTK inhibitors with special focus on ibrutinib in WaldenstrÃ¶m macroglobulinemia: An expert panel opinion statement. Hematological Oncology, 2022, 40, 332-340.	1.7	3
7	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2022, , 1-4.	1.3	3
8	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. Hematological Oncology, 2022, 40, 518-527.	1.7	4
9	Clonal haematopoiesis as a risk factor for therapyâ€related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemoâ€(immuno)therapy. British Journal of Haematology, 2022, 198, 103-113.	2.5	7
10	Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A realâ€life campus CLL study. American Journal of Hematology, 2022, 97, .	4.1	14
11	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. Cancers, 2022, 14, 207.	3.7	3
12	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia, 2021, 35, 235-238.	7.2	17
13	Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study. Haematologica, 2021, 106, 622-625.	3.5	39
14	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia, 2021, 35, 737-746.	7.2	61
15	Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients. Hematological Oncology, 2021, 39, 141-144.	1.7	3
16	Comparison of ibrutinib and idelalisib plus rituximab in realâ€life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	2.2	5
17	Assessment of the 4â€factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. American Journal of Hematology, 2021, 96, E168-E171.	4.1	10
18	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. Hematological Oncology, 2021, 39, 326-335.	1.7	8

#	Article	IF	Citations
19	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 637186.	2.8	17
20	<scp>TP53</scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 2021, 96, E306-E310.	4.1	8
21	Effectiveness of ibrutinib as firstâ€line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximabâ€bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 2021, 96, E269-E272.	4.1	3
22	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Blood, 2021, 137, 3507-3517.	1.4	30
23	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cancers, 2021, 13, 3240.	3.7	16
24	Management of chronic lymphocytic leukemia in Italy during a one year of the COVIDâ€19 pandemic and at the start of the vaccination program. A Campus CLL report. Hematological Oncology, 2021, 39, 570-574.	1.7	9
25	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 684621.	2.8	6
26	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Blood, 2021, 138, 2727-2730.	1.4	9
27	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. Blood Advances, 2021, , .	5.2	14
28	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	7.2	57
29	Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. Haematologica, 2021, 106, 1500-1503.	3.5	7
30	Increased eryptosis in patients with primary antiphospholipid syndrome (APS): a new actor in the pathogenesis of APS. Clinical and Experimental Rheumatology, 2021, 39, 838-843.	0.8	1
31	HIF-1Î± is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica, 2020, 105, 1042-1054.	3.5	39
32	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a realâ€world setting. A GIMEMAâ€ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	2.8	12
33	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisibâ€“rituximab. Blood Cancer Journal, 2020, 10, 92.	6.2	7
34	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood, 2020, 135, 1859-1869.	1.4	86
35	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. Blood, 2020, 136, 763-766.	1.4	33
36	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. Frontiers in Oncology, 2020, 10, 848.	2.8	5

#	Article	IF	Citations
37	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 2020, 34, 2354-2363.	7.2	198
38	Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. Cancers, 2020, 12, 1773.	3.7	4
39	Frontline treatment with the combination obinutuzumab Â± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. American Journal of Hematology, 2020, 95, 604-611.	4.1	12
40	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). Haematologica, 2020, 105, 2671-2674.	3.5	1
41	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood, 2020, 135, 1244-1254.	1.4	33
42	Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica, 2020, 105, 448-456.	3.5	64
43	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. British Journal of Haematology, 2020, 189, 853-859.	2.5	18
44	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. Blood, 2020, 136, 47-49.	1.4	1
45	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. Blood, 2020, 136, 23-25.	1.4	0
46	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. Blood, 2020, 136, 30-31.	1.4	0
47	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. Blood, 2020, 136, 33-34.	1.4	1
48	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood, 2020, 136, 45-49.	1.4	2
49	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. Blood, 2020, 136, 54-55.	1.4	2
50	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. Blood, 2020, 136, 25-26.	1.4	3
51	Biallelic <scp>BIRC</scp>3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. British Journal of Haematology, 2019, 185, 156-159.	2.5	9
52	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 508-512.	1.7	13
53	Venetoclax in CLL patients who progress after Bâ€cell Receptor inhibitor treatment: a retrospective multiâ€centre Italian experience. British Journal of Haematology, 2019, 187, e8-e11.	2.5	14
54	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-NaÃ¯ve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. Cancers, 2019, 11, 896.	3.7	16

#	Article	IF	Citations
55	Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. Leukemia Research, 2019, 87, 106233.	0.8	16
56	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. British Journal of Cancer, 2019, 121, 150-156.	6.4	31
57	Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica, 2019, 104, 2053-2060.	3.5	60
58	Unravelling the suboptimal response of <scp>TP</scp>53â€mutated chronic lymphocytic leukaemia to ibrutinib. British Journal of Haematology, 2019, 184, 392-396.	2.5	9
59	Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia. Blood, 2019, 134, 3516-3516.	1.4	2
60	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematological Oncology, 2018, 36, 624-632.	1.7	55
61	Gene mutations in lenalidomide-treated CLL. Blood, 2018, 131, 1769-1771.	1.4	2
62	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica, 2018, 103, 1209-1217.	3.5	30
63	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia, 2018, 32, 1869-1873.	7.2	8
64	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. British Journal of Haematology, 2018, 181, 229-233.	2.5	34
65	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. Journal of Experimental Medicine, 2018, 215, 681-697.	8.5	65
66	Comparison between the CLLâ€IPI and the <scp>B</scp>arcelonaâ€<scp>B</scp>rno prognostic model: Analysis of 1299 newly diagnosed cases. American Journal of Hematology, 2018, 93, E35-E37.	4.1	18
67	Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib. Lancet Oncology, The, 2018, 19, 7-8.	10.7	1
68	Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. Expert Review of Hematology, 2018, 11, 601-611.	2.2	10
69	Predictive value of the <scp>CLL</scp>â€<scp>IPI</scp> in <scp>CLL</scp> patients receiving chemoâ€immunotherapy as firstâ€line treatment. European Journal of Haematology, 2018, 101, 703-706.	2.2	8
70	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. American Journal of Hematology, 2018, 93, E216-E219.	4.1	15
71	Protective Role Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia: FOCUS on Subcutaneous Immunoglobulin Formulations. Blood, 2018, 132, 4954-4954.	1.4	3
72	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. Blood, 2018, 132, 3118-3118.	1.4	6

#	Article	IF	Citations
73	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 4412-4412.	1.4	2
74	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. Blood, 2018, 132, 1834-1834.	1.4	1
75	Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region. Blood, 2018, 132, 5550-5550.	1.4	0
76	The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 1844-1844.	1.4	0
77	TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. Blood, 2018, 132, 3119-3119.	1.4	1
78	Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. Lancet Oncology, The, 2017, 18, 270-271.	10.7	1
79	Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. American Journal of Hematology, 2017, 92, 529-535.	4.1	20
80	Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. Leukemia Research, 2017, 57, 65-71.	0.8	17
81	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. Haematologica, 2017, 102, e352-e355.	3.5	9
82	Clinical relevance of silent red blood cell autoantibodies. Haematologica, 2017, 102, e473-e475.	3.5	9
83	Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib. Chemotherapy, 2017, 62, 350-352.	1.6	1
84	Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase Iâ€“II GIMEMA trial. Leukemia and Lymphoma, 2017, 58, 1640-1647.	1.3	8
85	Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic workâ€up. American Journal of Hematology, 2016, 91, E319-20.	4.1	0
86	Interâ€•and intraâ€patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. British Journal of Haematology, 2016, 172, 371-383.	2.5	20
87	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood, 2016, 128, 2093-2095.	1.4	52
88	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. European Journal of Cancer, 2016, 60, 154-165.	2.8	22
89	A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for <scp>IGHV</scp>â€Dâ€J rearrangements and <scp>BRAF</scp>â€V600E mutation: lack of evidence for a common origin. British Journal of Haematology, 2016, 174, 329-331.	2.5	4
90	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€<scp>CLL</scp>1â€<scp>GISL</scp> study. European Journal of Haematology, 2016, 96, 36-45.	2.2	7

#	Article	IF	Citations
91	Management of elderly and unfit patients with chronic lymphocytic leukemia. Expert Review of Hematology, 2016, 9, 1165-1175.	2.2	6
92	Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. Leukemia and Lymphoma, 2016, 57, 2429-2431.	1.3	10
93	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. Blood, 2016, 128, 2038-2038.	1.4	3
94	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. Blood, 2016, 128, 3240-3240.	1.4	0
95	HIF-1Î± Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. Blood, 2016, 128, 305-305.	1.4	0
96	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood, 2015, 126, 1921-1924.	1.4	197
97	Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miRâ€132 and miRâ€212. Genes Chromosomes and Cancer, 2015, 54, 222-234.	2.8	26
98	Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. Leukemia Research, 2015, 39, 1066-1070.	0.8	29
99	Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study. Blood, 2015, 126, 2946-2946.	1.4	1
100	Is Idelalisib Cost-Effective for Refractory/Relapsed Chronic Lymphocytic Leukemia? a Decision Analysis in the Second-Line Setting. Blood, 2015, 126, 3305-3305.	1.4	3
101	A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients. Blood, 2015, 126, 2930-2930.	1.4	0
102	Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between Bâ€cell receptor structure, function, and patients' prognosis. American Journal of Hematology, 2014, 89, 74-82.	4.1	20
103	Chlorambucil plus rituximab with or without maintenance rituximab as firstâ€line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology, 2014, 89, 480-486.	4.1	104
104	Italian external and multicentric validation of the <scp>MD A</scp>nderson <scp>C</scp>ancer <scp>C</scp>enter nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. British Journal of Haematology, 2014, 167, 224-232.	2.5	25
105	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leukemia Research, 2014, 38, 1269-1277.	0.8	13
106	Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood, 2014, 123, 2378-2388.	1.4	78
107	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. Leukemia Research, 2014, 38, 198-203.	0.8	4
108	Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and <scp>ASO</scp> IgH <scp>RQ</scp>â€<scp>PCR</scp>. British Journal of Haematology, 2014, 166, 360-368.	2.5	27

#	Article	IF	Citations
109	NOTCH1, SF3B1, BIRC3andTP53mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. Leukemia and Lymphoma, 2014, 55, 2785-2792.	1.3	47
110	BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion. Blood, 2014, 124, 3295-3295.	1.4	3
111	Total body computed tomography scan in the initial workâ€up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€CLL1â€GISL study. American Journal of Hematology, 2013, 88, 539-544.	4.1	10
112	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood, 2013, 121, 1403-1412.	1.4	420
113	Chromosome 2p gain in monoclonal Bâ€cell lymphocytosis and in early stage chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 24-31.	4.1	27
114	Bâ€cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 32-36.	4.1	36
115	IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells. Leukemia Research, 2013, 37, 455-462.	0.8	7
116	Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. Haematologica, 2013, 98, 371-375.	3.5	15
117	ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica, 2012, 97, 47-55.	3.5	92
118	Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications. Leukemia and Lymphoma, 2012, 53, 1660-1665.	1.3	10
119	Behind the scenes of nonâ€nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. British Journal of Haematology, 2012, 156, 601-611.	2.5	21
120	An Italian retrospective study on the routine clinical use of lowâ€dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. British Journal of Haematology, 2012, 156, 481-489.	2.5	17
121	A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. Experimental Hematology, 2012, 40, 197-206.e1.	0.4	15
122	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. Leukemia Research, 2012, 36, 459-466.	0.8	7
123	NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment. Blood, 2012, 120, 1784-1784.	1.4	2
124	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 1780-1780.	1.4	0
125	Longitudinal analysis of human herpesvirus-8 DNA and antibodies in an Italian allogeneic stem cell transplant recipient. Journal of Clinical Virology, 2011, 52, 247-250.	3.1	5
126	Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. Haematologica, 2011, 96, 277-283.	3.5	47

#	Article	IF	Citations
127	Enteral nutrition may cause false-positive results of Aspergillus Galactomannan assay in absence of gastrointestinal diseases. Mycoses, 2011, 54, e883-e884.	4.0	16
128	5â€²-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. Leukemia Research, 2011, 35, 1409-1411.	0.8	3
129	Chronic lymphocytic leukemia in less fit patients: â€œslow-goâ€• Leukemia and Lymphoma, 2011, 52, 2207-2216.	1.3	18
130	The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience. American Journal of Hematology, 2011, 86, 1007-1012.	4.1	47
131	Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling. Genes Chromosomes and Cancer, 2011, 50, 263-274.	2.8	25
132	White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. Haematologica, 2011, 96, 626-630.	3.5	27
133	Is the Aberrant Expression of p53 by Immunocytochemistry a Surrogate Marker ofTP53Mutation and/or Deletion in Chronic Lymphocytic Leukemia?. American Journal of Clinical Pathology, 2011, 135, 173-174.	0.7	4
134	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. Blood, 2011, 118, 294-294.	1.4	6
135	Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors. Leukemia Research, 2010, 34, 733-741.	0.8	12
136	The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica, 2010, 95, 464-469.	3.5	37
137	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. Blood, 2010, 116, 2462-2462.	1.4	17
138	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. Blood, 2010, 116, 2471-2471.	1.4	2
139	Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study. Blood, 2010, 116, 1377-1377.	1.4	1
140	Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial. Blood, 2010, 116, 1360-1360.	1.4	2
141	Histopathological and molecular features of persistent polyclonal Bâ€cell lymphocytosis (PPBL) with progressive splenomegaly. British Journal of Haematology, 2009, 144, 726-731.	2.5	51
142	Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood, 2009, 114, 638-646.	1.4	65
143	Identification of monoclonal B-cell lymphocytosis among sibling transplant donors for chronic lymphocytic leukemia patients. Blood, 2009, 114, 2848-2849.	1.4	20
144	Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. British Journal of Haematology, 2008, 142, 202-215.	2.5	206

#	Article	IF	Citations
145	BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. Blood, 2008, 112, 782-792.	1.4	121
146	Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. Blood, 2008, 111, 5691-5693.	1.4	30
147	A Prospective Study of Young Chronic Lymphocytic Leukemia (CLL) Patients Investigated at Diagnosis: Distribution and Clinical Significance of Prognostic Factors. Blood, 2008, 112, 3121-3121.	1.4	0
148	ATM Gene Alterations in CLL Patients Induce Gene Profile Clusters and Predict Disease Progression.. Blood, 2008, 112, 2084-2084.	1.4	0
149	A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood, 2007, 110, 3326-3333.	1.4	79
150	Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood, 2007, 109, 4944-4951.	1.4	471
151	IgVH Germline and Mutated Chronic Lymphocytic Leukemia (CLL) Cases Exert a Diverse Responsiveness upon BCR Ligation.. Blood, 2007, 110, 1133-1133.	1.4	1
152	The MicroRNA (miR) Profile in B-Cell Chronic Lymphocytic Leukemia (CLL) Reveals a Differential Expression of miR-21, miR-155 and miR-150 between Leukemic and Normal B Lymphocytes, and of miR-150, miR-29bc and miR-223 between IgVH Mutated and Unmutated Patients.. Blood, 2006, 108, 298-298.	1.4	1
153	Gene Expression Profile of Protein Kinases Reveals a Distinctive Signature of Chronic Lymphocytic Leukemia (CLL) and Points to a Role of Second Generation Protein Kinase Inhibitors.. Blood, 2006, 108, 2794-2794.	1.4	0
154	Histopathologic and Molecular Features of Persistent Polyclonal B-Cell Lymphocytosis Challenging the Benign Nature of the Disorder.. Blood, 2006, 108, 4612-4612.	1.4	0
155	Chronic Lymphocytic Leukemia (CLL) with Discordance in ZAP-70 Expression and IgVH Mutation Status.. Blood, 2006, 108, 2787-2787.	1.4	0
156	Angiogenic Activity in IgVH Mutated and Unmutated Chronic Lymphocytic Leukemia (CLL): Indications for the Therapeutic Use of VEGF-Signaling Inhibitors.. Blood, 2006, 108, 2819-2819.	1.4	0
157	Clinical features and outcome of familial chronic lymphocytic leukemia. Haematologica, 2006, 91, 1117-20.	3.5	35
158	Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica, 2006, 91, 1689-92.	3.5	61
159	Bullous lesions in chronic lymphocytic leukaemia: pemphigoid or insect bites?. Acta Dermato-Venereologica, 2006, 86, 74-76.	1.3	13
160	New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. Current Opinion in Oncology, 2005, 17, 597-604.	2.4	21
161	The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. British Journal of Haematology, 2005, 130, 549-557.	2.5	51
162	Familial Cancer Associated with a Polymorphism inARLTS1. New England Journal of Medicine, 2005, 352, 1667-1676.	27.0	119

#	Article	IF	Citations
163	A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma, 2005, 46, 553-560.	1.3	21
164	A High-Density SNP Genomewide Linkage Scan for Chronic Lymphocytic Leukemiaâ€“Susceptibility Loci. American Journal of Human Genetics, 2005, 77, 420-429.	6.2	65
165	Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19+ cells in vivo and in vitro. British Journal of Haematology, 2004, 125, 720-728.	2.5	27
166	Immunoglobulin (Ig) Variable Gene Usage Identifies a Subset of Unmutated Chronic Lymphocytic Leukemia (CLL) Patients Expressing 51p1-Like alleles and a Particularly Unfavorable Prognostic Outcome.. Blood, 2004, 104, 1922-1922.	1.4	0
167	Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood, 2003, 102, 1035-1041.	1.4	74
168	Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. British Journal of Haematology, 2001, 113, 391-399.	2.5	26
169	Hodgkin / Reed-Sternberg cells and Hodgkin's disease in patients with B-cell chronic lymphocytic leukaemia: an immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenetic background. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 129-132.	2.8	42
170	Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood, 2000, 95, 2786-2792.	1.4	261
171	Clinical Characteristics and Outcome of Young Chronic Lymphocytic Leukemia Patients: A Single Institution Study of 204 Cases. Blood, 1999, 94, 448-454.	1.4	203
172	V_H gene usage by family members affected with chronic lymphocytic leukaemia. British Journal of Haematology, 1999, 107, 616-624.	2.5	45
173	p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. Blood, 1998, 91, 4342-4349.	1.4	176
174	Late listeriosis after fludarabine plus prednisone treatment. British Journal of Haematology, 1994, 87, 407-408.	2.5	14
175	Monocytopenia and infections in chronic lymphocytic leukemia (CLL). European Journal of Haematology, 1991, 46, 119-119.	2.2	12
176	Standard conditioning regimen and t-depleted donor bone marrow for transplantation in chronic myeloid leukemia. Leukemia Research, 1986, 10, 1469-1475.	0.8	14